Objective
For improved protection from HIV infection during birth or through accidental exposure to HIV, antibodies with broad neutralizing activity would be a valuable addition to antiretroviral treatment and to vaccines. So far in the field of HIV applied resear ch only few antibodies with broad cross clade neutralizing properties are available (b12, 2G12, 2F5 and 4E10). They recognize either epitopes presented only transiently during infection of cells, or epitopes not recognizable by unmodified immunoglobulins (2G12). Two experimental strategies are used in separate and in combination. One uses the lead given by extremely rare mutant antibody genes (ie 2G12) to generate mice with germ line modified immunoglobulin genes which introduce extended mobility into th e immunoglobulin protein backbone. Immunisation of these mice will allow recognition of novel expanded epitopes including glycane clusters and the development of monoclonal antibody. The other line of experiments employs HIV receptor-transgenic mice for i mmunization to favour receptor mediated transitory stages of the viral envelope. Previous experience and reagents from earlier EU funded programmes (virosome incorporating HIV proteins PN 012183) and new microbicide-vaccine combinations against HIV (subm. call LSH-2004-2.3.0-1 with R. Shattock) to present native oligomeric HIV envelope of clinically relevant HIV isolates will be used in addition to liposome presented recombinant C-clade gp 140 oligomers and gp160 encoding highly effective DNA plasmid vacc ines in CD4 transgenic mice to generate monoclonal antibodies with novel broadly neutralizing properties. This proof of principle can directly give valuable reagents. It can also be further developed into humanized antibodies. The novel antibodies develo ped out of this programme will be valuable additions to the immunogens developed by the EUROVAC group in the context of FP5. The C-clade chosen is of major importance in the worldwide HIV epidemic.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine immunology immunisation
- natural sciences biological sciences genetics DNA
- natural sciences biological sciences biochemistry biomolecules proteins
- medical and health sciences health sciences infectious diseases RNA viruses HIV
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP6-2004-LIFESCIHEALTH-5
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
REGENSBURG
Germany
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.